XTL Biopharmaceuticals LTD revenue

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

XTL Biopharmaceuticals LTD: revenue history, annual

Fiscal year	2024Dec 2024
Revenue	451
Gross profit	3
Gross margin	0.7%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
XTL Biopharmaceuticals LTD	$451,000	—	—
Cardiff Oncology, Inc.	$508,000	-7.0%	7.2%
Cervomed Inc.	$331,295	-95.7%	-52.7%
Medicinova Inc	$920,481	875.7%	—
Shattuck Labs, Inc.	$1.0m	-66.6%	5.2%
Clene Inc.	$197,000	-31.1%	-36.9%

Compare with peers

• Cardiff Oncology, Inc. revenue
• Cervomed Inc. revenue
• Medicinova Inc revenue
• Shattuck Labs, Inc. revenue
• Clene Inc. revenue

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from XTL Biopharmaceuticals LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to XTL Biopharmaceuticals LTD.